UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.6801-6801

2023

Volltextzugriff (PDF)

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.6900-6900

2023

Volltextzugriff (PDF)

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.2344-2344

2023

Volltextzugriff (PDF)

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience

Blood, 2023-11, Vol.142 (Supplement 1), p.3361-3361

2023

Volltextzugriff (PDF)

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Blood, 2023-11, Vol.142 (Supplement 1), p.4885-4885

2023

Volltextzugriff (PDF)

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Blood, 2023-11, Vol.142 (Supplement 1), p.6916-6916

2023

Volltextzugriff (PDF)

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.6914-6914

2023

Volltextzugriff (PDF)

Dietary Intervention in Glaucoma

US Ophthalmic Review, 2022, Vol.16 (1), p.22

2022

Volltextzugriff (PDF)

POSTER: CT-216 Safety and Efficacy of Eltrombopag in Patients With Post-CAR T Cytopenias: Real-World Experience

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S229-S229

2023

Volltextzugriff (PDF)

CT-216 Safety and Efficacy of Eltrombopag in Patients With Post-CAR T Cytopenias: Real-World Experience

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S522-S523

2023

Volltextzugriff (PDF)

Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias

European journal of haematology, 2024-04, Vol.112 (4), p.538-546

2024

Volltextzugriff (PDF)

POSTER: CT-359 Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S231-S231

2023

Volltextzugriff (PDF)

CT-359 Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S528-S529

2023

Volltextzugriff (PDF)

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

Hematological oncology, 2024-07, Vol.42 (4), p.e3293-n/a

2024

Volltextzugriff (PDF)

BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T?

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S194-S195

2024

Volltextzugriff (PDF)

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S205-S206

2024

Volltextzugriff (PDF)

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S208-S208

2024

Volltextzugriff (PDF)

Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S373-S373

2024

Volltextzugriff (PDF)

Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S323-S323

2024

Volltextzugriff (PDF)

Perceptions of health care providers and parents related to benefits and predisposition factors of skin-to-skin contact

International Journal Of Community Medicine And Public Health, 2022-08, Vol.9 (9), p.3396

2022

Volltextzugriff (PDF)

Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

Transplantation and cellular therapy, 2024-09, Vol.30 (9), p.876-884

2024

Volltextzugriff (PDF)

A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S207-S208

2024

Volltextzugriff (PDF)

Pattern of Antimicrobial Susceptibility for Salmonella Typhi in Dhaka Medical College Hospital from 2013-2014

Journal of Dhaka Medical College, 2017-09, Vol.25 (2), p.115-118

2017

Volltextzugriff (PDF)

Pulmonary Mucormycosis

Electronic journal of general medicine, 2014-01, Vol.11 (1)

2014

Volltextzugriff (PDF)

Infections by Pseudomonas aeruginosa and Antibiotic Resistance Pattern of the Isolates from Dhaka Medical College Hospital

Bangladesh journal of medical microbiology, 2016-05, Vol.1 (2), p.48-51

2016

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(54)
Bücher
(1)

Sprache

Englisch
(55)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

Dietary Intervention in Glaucoma

POSTER: CT-216 Safety and Efficacy of Eltrombopag in Patients With Post-CAR T Cytopenias: Real-World Experience

CT-216 Safety and Efficacy of Eltrombopag in Patients With Post-CAR T Cytopenias: Real-World Experience

Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias

POSTER: CT-359 Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma

CT-359 Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T?

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest

Perceptions of health care providers and parents related to benefits and predisposition factors of skin-to-skin contact

Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients

Pattern of Antimicrobial Susceptibility for Salmonella Typhi in Dhaka Medical College Hospital from 2013-2014

Pulmonary Mucormycosis

Infections by Pseudomonas aeruginosa and Antibiotic Resistance Pattern of the Isolates from Dhaka Medical College Hospital

Aktive Filter

Suchergebnisse filtern